RxDoctor Payments Data

Davisson Edmond, MD

Family Medicine · Oxford, ALNPI 1376739151

Payments from drug & device makers

$7,178in general payments, 2019–2025

Across 499 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Boehringer Ingelheim$973
  • Bayer$483
  • Supernus Pharmaceuticals, Inc.$409
  • Lilly USA, LLC$383
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$7,178100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,178 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$127,395
Medicare patients
279
Services billed
3,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin144$126,837
FarxigaDapagliflozin Propanediol142$118,187
MounjaroTirzepatide63$82,798
OzempicSemaglutide59$82,319
RybelsusSemaglutide63$64,366
Tresiba Flextouch U-200Insulin Degludec66$58,668
ProliaDenosumab27$46,807
JanuviaSitagliptin Phosphate43$43,519
TrulicityDulaglutide24$39,473
EliquisApixaban20$25,308
KerendiaFinerenone20$24,246
MyrbetriqMirabegron18$23,586
Tresiba Flextouch U-100Insulin Degludec16$21,085
XareltoRivaroxaban23$15,526
LinzessLinaclotide11$14,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,515$146,685122 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta$973$139,423167 claims
AstraZenecaFarxiga, Symbicort$308$127,743170 claims
Lilly USA, LLCMounjaro, Trulicity$383$122,27187 claims
AmgenProlia$232$46,80727 claims
PfizerEliquis$169$25,30820 claims
BayerKerendia$483$24,24620 claims
GSKTrelegy Ellipta, Incruse Ellipta$178$20,31432 claims
Johnson & JohnsonXarelto$146$15,52623 claims
AbbVieLinzess$1,316$14,04711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Oxford

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →